Your session is about to expire
← Back to Search
ALA + Radiation for Solid Cancers
Study Summary
This trial is testing a new cancer treatment consisting of two drugs, ALA and RT. The purpose of the trial is to find the maximum tolerated doses of the drugs and to assess the safety and preliminary efficacy of the treatment. The trial will enroll at least 20 patients across a variety of tumor types.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: ALA / Fractions of Radiotherapy
Frequently Asked Questions
What is the projected size of this experiment's cohort?
"Affirmative. As per the information on clinicaltrials.gov, this medical experiment is currently acquiring participants after being initially advertised on July 30th 2020 and last updated February 18th 2022. The investigators are looking to include 130 patients from 1 site within their study population."
Are there any openings left to participate in this research endeavor?
"Affirmative. Information available on clinicaltrials.gov verifies that this trial is actively recruiting upon its initial posting in July 30th 2020, and the most recent update made was February 18 2021; 130 participants are needed from one site to complete the study."
Have the FDA granted approval to Low dose radiation and ALA?
"Due to the limited amount of data regarding safety and efficacy, Low dose radiation and ALA have been assessed as having a 1 rating on a scale from 1 to 3."
Share this study with friends
Copy Link
Messenger